The reported main side effects of copanlisib are mostly infusion-related including transient hyperglycemia, which is an expected on-target effect of PI3Kα inhibition that is related to insulin-receptor signaling [28, 29]. The gene discussed is INSR; the disease is Hyperglycemia.